Ketamine for Depression: A Powerful but Tricky Solution

Ketamine, a potent anesthetic known on the street as "special K" for its hallucinogenic and dissociative properties, has emerged as a significant treatment in psychiatry. Functioning as an NMDA receptor antagonist, its antidepressant effects are believed to stem from a metabolite, rather than the parent drug itself. At doses lower than those used for anesthesia, ketamine rapidly alleviates depression and is considered the most effective drug currently available for treating suicidality, even surpassing lithium. The initial evidence for its rapid antidepressant action was demonstrated in randomized controlled trials as early as 2000.

Ketamine is typically administered via IV infusion over 40 minutes, during which patients may experience temporary hallucinations or derealization, effects that usually subside within minutes to a couple of hours. While patients can feel better within 24 hours, the antidepressant effect of a single infusion is short-lived, lasting only about five to seven days, with some residual improvement for a week or two. To maintain efficacy, multiple infusions are often necessary, or patients may transition to a ketamine nasal spray. While compounded nasal ketamine has been available, esketamine (Spravato), a commercial formulation by Janssen Pharmaceuticals, has received FDA approval for treatment-resistant depression and depression with imminent risk of suicide, streamlining access by eliminating the need for compounding pharmacies.

However, the Spravato protocol is stringent and demanding. It involves twice-weekly treatments for the first four weeks, then once weekly for the subsequent four weeks, followed by maintenance doses either weekly or every two weeks. Patients must attend a doctor's office registered within a specific monitoring system, self-administer the spray, and remain under observation for two hours post-treatment, requiring a designated driver for transportation home. This regimen necessitates a substantial time commitment and likely incurs charges for monitoring appointments, even if a doctor isn't directly seen. Common side effects include dissociation, nausea, dizziness, and drowsiness.

Despite its groundbreaking potential for severe and treatment-resistant depression, ketamine therapy faces significant practical hurdles. Cost is a major concern; IV infusions can range from $250 to $300 each, and nasal spray from $45 to $125 per dose, often not covered by insurance, especially for off-label IV use. Finding qualified providers, particularly for IV infusions, can be challenging outside major metropolitan areas. The efficacy of the nasal spray is also speculated to be less potent or long-lasting compared to direct intravenous administration, underscoring the ongoing complexities in its application, accessibility, and integration into standard psychiatric care.

ketamine is a very powerful anesthetic drug that's made its way into psychiatry

it's a hallucinogen and induces dissociation which is detachment from your environment

not only does it improve depression but it removes it quickly and it's the best drug we have so far to treat suicidality even better than lithium

the antidepressant effect only lasts about five to seven days but you can get some lower level of improvement that lasts maybe or week or two from that single infusion

s ketamine is a commercial formulation that's still in the approval phase to be used for treatment-resistant depression and depression with imminent risk of suicide

newsflash since I made this video the FDA has approved privado

you can't just go pick it up from the pharmacy and do it yourself you have to go to your doctor's office and that doctor has to be registered within this monitoring system

despite all these little nitty-gritty details this is still a breakthrough in the treatment of treatment resistant depression